{"ok":true,"entity":{"id":"glp-1-receptor-agonist","name":"GLP-1 receptor agonist","entityType":"concept","officialName":"GLP-1 (glucagon-like peptide-1) receptor agonist","canonicalName":"GLP-1 receptor agonist","displayName":"GLP-1 receptor agonist","category":"薬剤クラス（糖尿病・体重管理に用いられるGLP-1作動薬）","shortDescription":"GLP-1受容体作動薬は、ホルモンのGLP-1（glucagon-like peptide-1）に似た働きをする薬剤クラスで、NIDDKは食後の血糖上昇を抑え、空腹感を減らす可能性があるが、インスリンの代わりにはならないと説明している。NIDDKは、FDAが長期の体重管理用に承認した薬としてliraglutide（Saxenda）、semaglutide（Wegovy）、tirzepatide（Zepbound）を挙げている（2024年6月更新の記載）。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity","updatedAt":"2026-10-29T04:31:31.488Z","secondaryClusters":[],"alias":["GLP-1受容体作動薬","GLP-1 receptor agonists"],"searchKeywords":["GLP-1受容体作動薬","GLP-1作動薬","GLP-1 receptor agonist","glucagon-like peptide-1","semaglutide","tirzepatide","liraglutide","体重管理"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}